Beone Medicines (ONC) Fundamental Analysis: Revenue, Earnings & Valuation

3.40 / 10

Netural

Fundamental rating is Neutral with a 3.4/10 score. Inventory turnover (1.212) and receivables turnover (6.93) are modest strengths, while PB‑ROE (2.94) is a weakness. Overall, the company shows challenging fundamentals despite decent cash‑up and asset‑MV metrics.

Analysis Checks(9/10)

Total operating revenue (YoY growth rate %)

Value40.23

Score2/3

Weight4.05%

1M Return1.42%

Inventory turnover ratio

Value1.21

Score2/3

Weight-0.73%

1M Return-0.26%

Accounts receivable turnover ratio

Value6.93

Score3/3

Weight0.57%

1M Return0.21%

PB-ROE

Value2.94

Score0/3

Weight13.16%

1M Return4.13%

Income tax / Total profit (%)

Value31.17

Score2/3

Weight2.57%

1M Return0.80%

Cash-UP

Value-0.04

Score3/3

Weight31.96%

1M Return7.46%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.97

Score2/3

Weight-0.81%

1M Return-0.30%

Operating revenue (YoY growth rate %)

Value40.23

Score2/3

Weight4.39%

1M Return1.53%

Cost of sales ratio (%)

Value12.51

Score3/3

Weight3.13%

1M Return1.05%

Asset-MV

Value-0.55

Score2/3

Weight41.70%

1M Return11.96%

Is ONC undervalued or overvalued?

ONC scores 3.40/10 on fundamentals and holds a Fair valuation at present. Backed by its 7.46% ROE, 5.37% net margin, 109.84 P/E ratio, 7.23 P/B ratio, and 142.55% earnings growth, these metrics solidify its Netural investment rating.